60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
60 Degrees Pharmaceuticals (NASDAQ:SXTP), a company focused on developing medicines for vector-borne diseases, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation on September 10 at 2:30 ET. Management will also conduct one-on-one meetings during the conference. The presentation will be available via webcast with replay access for approximately 90 days on the company's investor relations website.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), azienda impegnata nello sviluppo di farmaci per malattie trasmesse da vettori, parteciperà alla H.C. Wainwright 27ª Annual Global Investment Conference dall'8 al 10 settembre 2025 presso il Lotte New York Palace Hotel.
Il CEO, Dr. Geoff Dow, terrà una presentazione in diretta il 10 settembre alle 14:30 ET. Il management sarà inoltre disponibile per incontri one‑to‑one durante la conferenza. La presentazione sarà trasmessa via webcast e resterà disponibile in replay per circa 90 giorni sul sito di investor relations della società.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), una compañía centrada en el desarrollo de medicamentos para enfermedades transmitidas por vectores, participará en la H.C. Wainwright 27th Annual Global Investment Conference del 8 al 10 de septiembre de 2025 en el Lotte New York Palace Hotel.
El CEO, Dr. Geoff Dow, ofrecerá una presentación en directo el 10 de septiembre a las 14:30 ET. La dirección también celebrará reuniones individuales durante la conferencia. La presentación estará disponible por webcast con reproducción durante aproximadamente 90 días en la web de relaciones con inversores de la compañía.
60 Degrees Pharmaceuticals (NASDAQ:SXTP)는 벡터 매개 질환 치료제 개발에 주력하는 회사로, 2025년 9월 8일부터 10일까지 롯데 뉴욕 팰리스 호텔에서 열리는 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 참가합니다.
CEO인 Dr. Geoff Dow는 9월 10일 동부 표준시(ET) 기준 오후 2시 30분에 라이브 프레젠테이션을 진행합니다. 경영진은 컨퍼런스 기간 동안 일대일 미팅도 진행할 예정입니다. 프레젠테이션은 웹캐스트로 제공되며 회사 투자자 관계 웹사이트에서 약 90일간 다시보기가 가능합니다.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), une société axée sur le développement de médicaments contre les maladies transmises par vecteurs, participera à la H.C. Wainwright 27th Annual Global Investment Conference du 8 au 10 septembre 2025 au Lotte New York Palace Hotel.
Le PDG, Dr. Geoff Dow, fera une présentation en direct le 10 septembre à 14h30 ET. La direction tiendra également des réunions individuelles pendant la conférence. La présentation sera diffusée en webcast et restera disponible en replay pendant environ 90 jours sur le site relations investisseurs de la société.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), ein Unternehmen, das sich auf die Entwicklung von Arzneimitteln gegen von Vektoren übertragene Krankheiten spezialisiert hat, wird an der H.C. Wainwright 27th Annual Global Investment Conference vom 8. bis 10. September 2025 im Lotte New York Palace Hotel teilnehmen.
CEO Dr. Geoff Dow wird eine Live-Präsentation am 10. September um 14:30 ET halten. Das Management wird während der Konferenz außerdem Einzelgespräche führen. Die Präsentation wird per Webcast verfügbar sein und etwa 90 Tage lang als Wiederholung auf der Investor-Relations-Website des Unternehmens abrufbar sein.
- None.
- None.
WASHINGTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today it will participate in the H.C. Wainwright (HCW) 27th Annual Global Investment Conference at the Lotte New York Palace Hotel, September 8-10, 2025.
Dr. Geoff Dow, CEO, will be presenting live on Wednesday, September 10, at 2:30 ET, and Company management will be conducting 1x1 meetings during the conference.
Conference attendees are invited to request meetings with management via the conference portal, through their HCW representative, or directly with the Company at the investor contact listed below.
The webcast will be available to watch live, and a replay will be available for approximately 90 days following the presentation on the 60 Degrees Pharmaceuticals investor page, https://investors.60degreespharma.com/news-events/presentations
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.
The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.
Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
FAQ
When is 60 Degrees Pharmaceuticals (SXTP) presenting at the H.C. Wainwright Conference?
How can investors watch the SXTP presentation at the H.C. Wainwright Conference?
Who will be presenting for 60 Degrees Pharmaceuticals at the H.C. Wainwright Conference?
How can investors schedule meetings with SXTP management at the conference?
